Is 89bio, Inc. (ETNB) a Buy, Sell, or Hold?
89bio, Inc.
NASDAQ:ETNB
$14.84 USD
$0 (0.0%)
- Volume
- 38.51M
- Average Volume
- 5.39M
- Market Capitalization
- $2.2B
- P/E Ratio
- -12.37
- Dividend Yield
- 0.00%
- Price Target
- $14.50
- Year High
- $15.06
- Year Low
- $4.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.19
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Rohan Palekar |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ETNB |
| CUSIP | 282559103 |
| CIK | 0001785173 |
| Web | https://www.89bio.com |
| Phone | 415 432 9270 |
| Currency | USD |
| Employees | 93 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 15.19 |
| Quick Ratio | 15.19 |
| Cash Ratio | 3.26 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -1.09 |
| Price / Cash Flow | -12.78 |
| Price / Book | 4.49 |
Price Target and Rating
| Average Stock Price Forecast | $14.50 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | 2.34% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$3.51 |
| Trailing P/E Ratio | -12.37 |
| PEG Ratio | 0.21 |
| P/E Growth | 0.21 |
| Net Income | -$367.08M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -32.43% |
| Return on Assets | -30.29% |
Financials Score
| AltmanZ Score | 12.50 |
| Piotroski Score | 2.00 |
| Working Capital | 561.91M |
| Total Assets | 603.48M |
| Ebit | -445.43M |
| Market Cap | 2.2B |
| Total Liabilities | 81.75M |
Poll Results
About 89bio, Inc. (NASDAQ:ETNB) Stock
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California. ...
Frequently Asked Questions
-
What is the current 89bio, Inc. (ETNB) stock price?
-
89bio, Inc.(NASDAQ:ETNB) stock price is $14.84 in the last trading session. During the trading session, ETNB stock reached the peak price of $15.06 while $4.16 was the lowest point it dropped to. The percentage change in ETNB stock occurred in the recent session was 0.0% while the dollar amount for the price change in ETNB stock was $0.
-
ETNB's industry and sector of operation?
-
The NASDAQ listed ETNB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ETNB?
-
Quoc Le-Nguyen | Chief Technical Officer
Rohan Palekar | Chief Executive Officer & Director
Harry Mansbach | Chief Medical Officer
Francis W. Sarena | Chief Operating Officer
Ryan Stephen Martins | Chief Financial Officer -
How many employees does ETNB have?
-
Number of ETNB employees currently stands at 93. ETNB operates from 142 Sansome Street, San Francisco, CA 94104, US.
-
Link for ETNB official website?
-
Official Website of ETNB is: https://www.89bio.com
-
How do I contact ETNB?
-
ETNB could be contacted at phone #415 432 9270 and can also be accessed through its website. ETNB operates from 142 Sansome Street, San Francisco, CA 94104, US.
-
How many shares of ETNB are traded daily?
-
The average number of ETNB shares traded daily for last 3 months was 5.39M.
-
What is the market cap of ETNB currently?
-
The market value of ETNB currently stands at $2.2B with its latest stock price at $14.84